Article Text

Download PDFPDF

LB-008 Treatment outcomes for ARUBA eligible brain arteriovenous malformations: a comparison of real-world data from the NVQI-QOD AVM registry to the ARUBA trial
  1. A Alrohimi,
  2. R Achey,
  3. R Abdalla,
  4. T Patterson,
  5. Y Moazeni,
  6. P Rasmussen,
  7. G Toth,
  8. M Bain,
  9. S Ansari,
  10. S Hussain,
  11. N Moore
  1. Cleveland Clinic, Cleveland, OH, Northwestern University, Chicago, IL


Introduction Significant controversy exists in the management of unruptured cerebral arteriovenous malformations (AVM). Results from A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) suggested that intervention increases the risk of stroke/death compared to medical management. However, numerous study limitations raised concerns regarding the trial’s generalizability. We assessed the rate of stroke/death and functional outcomes in ARUBA-eligible patients from a multicenter database, the Neurovascular Quality Initiative Quality Outcomes Database (NVQI-QOD).

Methods We performed a retrospective analysis of prospectively-collected data of ARUBA-eligible patients who underwent intervention at 18 participating centers. The primary endpoint was stroke/death from any cause. Secondary endpoints included neurologic, systemic, radiographic, and functional outcomes.

Results 173 ARUBA-eligible patients underwent intervention with median follow-up of 269 (25-733) days. Seventy-five patients received microsurgery ± embolization, 37 received radiosurgery, and 61 received embolization. Baseline demographics, risk factors, and general AVM characteristics were similar between groups. A total of 15 (8.7%) patients experienced stroke/death with no significant difference in primary outcome between treatment modalities. Microsurgery ± embolization was more likely to achieve AVM obliteration (P < 0.001). Kaplan-Meier survival curves demonstrated no difference in overall death/stroke outcomes between the different treatment modalities (P = 0.146). Additionally, when compared to the ARUBA interventional arm, our patients were significantly less likely to experience death/stroke (8.7% vs. 30.7%; P < 0.001) and functional impairment (mRS ≥ 2) (17% vs. 46.2%; P < 0.001).

Conclusion Our results suggest that intervention for unruptured brain AVMs at specialized centers across the United States is safe and effective.

Disclosures A. Alrohimi: None. R. Achey: None. R. Abdalla: None. T. Patterson: None. Y. Moazeni: None. P. Rasmussen: None. G. Toth: None. M. Bain: None. S. Ansari: None. S. Hussain: None. N. Moore: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.